Tag: Cutaneous t cell lymphoma

First developed for military purposes, a nitrogen mustard derivative was later recognized for its potent therapeutic effects on certain cancers. The answer to "is nitrogen mustard approved by the FDA?" is yes, although the original intravenous formulation has been discontinued in the United States, and a topical gel for skin lymphoma remains in use.

In clinical trials, up to 50% of patients receiving higher doses of bexarotene developed hypothyroidism, making it one of the most frequent adverse effects of the medication. This is the most significant answer when addressing **What are the side effects of bexarotene for thyroid?**, as the drug directly impacts thyroid hormone regulation.

First approved by the FDA in 1999 for the treatment of cutaneous T-cell lymphoma (CTCL), bexarotene is a synthetic retinoid with a highly specific mechanism of action. It is considered a 'rexinoid' due to its ability to selectively bind to and activate retinoid X receptors (RXRs).

First approved by the FDA in 1999 for the treatment of cutaneous T-cell lymphoma (CTCL), the medication known as **bexarotene** is a member of the retinoid drug family. However, it is a distinct subclass of retinoids, often called rexinoids, because it selectively targets retinoid X receptors (RXRs) rather than retinoic acid receptors (RARs).

According to the Cutaneous Lymphoma Foundation, bexarotene gel (brand name Targretin) is a topical retinoid approved for the treatment of early-stage cutaneous T-cell lymphoma (CTCL) in patients who have not responded to, or tolerated, other therapies. This specialized gel works directly on skin lesions to help manage the symptoms of this rare skin cancer.